Ginsenoside Re inhibits non-small cell lung cancer progression by suppressing macrophage M2 polarization induced by

Xiaoyu Tang1,2, Man Zhu1,2, Zeren Zhu1,2

  • 1School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, People's Republic of China.

PubMed

Insights

Ginsenoside Re inhibits the AMPKα1/STING feedback loop in non-small cell lung cancer (NSCLC) macrophages, reducing M2 polarization and metastasis. This study reveals a novel therapeutic strategy for NSCLC immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Tumor-associated macrophages (TAMs) in non-small cell lung cancer (NSCLC) promote metastasis.
  • Ginsenoside Re exhibits anticancer properties by modulating the immune system.
  • AMP-activated protein kinase (AMPK) and Sting (STING) pathway regulate macrophage polarization and tumor progression.

Purpose of the Study:

  • To investigate the regulatory relationship between AMPK and STING in NSCLC TAMs.
  • To elucidate the mechanism by which ginsenoside Re affects MΦ polarization and NSCLC metastasis.
  • To provide mechanistic evidence for ginsenoside Re's antimetastatic effects in NSCLC immunotherapy.

Main Methods:

  • Constructed cell culture and conditioned media (CM) systems.
  • Utilized RT-PCR, Western blotting, flow cytometry, and immunofluorescence to analyze MΦ polarization.
  • Assessed ginsenoside Re's effects on TAM phenotype and tumor progression in mouse models.

Main Results:

  • Identified an AMPKα1/STING positive feedback loop in NSCLC TAMs that drives M2 polarization and promotes NSCLC cell migration.
  • Demonstrated that ginsenoside Re inhibits M2-like MΦ polarization by disrupting the AMPKα1/STING feedback loop.
  • Showed that ginsenoside Re inhibits NSCLC cell migration and epithelial-mesenchymal transition (EMT) in vitro and suppresses tumor growth in vivo.

Conclusions:

  • Ginsenoside Re effectively modulates MΦ polarization by inhibiting the AMPKα1/STING positive feedback loop.
  • Ginsenoside Re exhibits significant antimetastatic effects in NSCLC.
  • Ginsenoside Re holds potential as a therapeutic agent for NSCLC immunotherapy.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K